Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy.
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has Merit Medical Systems's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MM3's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: MM3 underperformed the German Medical Equipment industry which returned 20.4% over the past year.
Return vs Market: MM3 underperformed the German Market which returned -0.7% over the past year.
Price Volatility Vs. Market
How volatile is Merit Medical Systems's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Merit Medical Systems undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MM3 (€40.2) is trading above our estimate of fair value (€35.38)
Significantly Below Fair Value: MM3 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MM3 is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: MM3 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MM3's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MM3 is good value based on its PB Ratio (2.7x) compared to the DE Medical Equipment industry average (4.6x).
How is Merit Medical Systems forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MM3 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: MM3 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MM3's is expected to become profitable in the next 3 years.
Revenue vs Market: MM3's revenue (7% per year) is forecast to grow faster than the German market (5.8% per year).
High Growth Revenue: MM3's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MM3's Return on Equity is forecast to be low in 3 years time (8.6%).
How has Merit Medical Systems performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MM3 is currently unprofitable.
Growing Profit Margin: MM3 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MM3 is unprofitable, and losses have increased over the past 5 years at a rate of -3.9% per year.
Accelerating Growth: Unable to compare MM3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MM3 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.2%).
Return on Equity
High ROE: MM3 has a negative Return on Equity (-0.41%), as it is currently unprofitable.
How is Merit Medical Systems's financial position?
Financial Position Analysis
Short Term Liabilities: MM3's short term assets ($462.5M) exceed its short term liabilities ($165.3M).
Long Term Liabilities: MM3's short term assets ($462.5M) do not cover its long term liabilities ($644.2M).
Debt to Equity History and Analysis
Debt Level: MM3's debt to equity ratio (47.9%) is considered high.
Reducing Debt: MM3's debt to equity ratio has reduced from 48% to 47.9% over the past 5 years.
Debt Coverage: MM3's debt is well covered by operating cash flow (20.7%).
Interest Coverage: MM3 is unprofitable, therefore interest payments are not well covered by earnings.
What is Merit Medical Systems's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MM3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MM3's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MM3's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MM3's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MM3's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fred Lampropoulos (70yo)
Mr. Fred P. Lampropoulos has been the President of BioSphere Medical, Inc. since September 2010. Mr. Lampropoulos serves as the Chairman and Chief Executive Officer of Merit Medical Systems Inc. He has bee ...
CEO Compensation Analysis
Compensation vs Market: Fred's total compensation ($USD5.05M) is above average for companies of similar size in the German market ($USD2.41M).
Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.
|CFO & Treasurer||2.17yrs||US$1.17m||0.0053% $116.7k|
|Chief Operating Officer||6.5yrs||US$1.23m||0.038% $852.3k|
|Executive Vice President of Commercial||1.92yrs||US$1.21m||no data|
|President of International Division||5yrs||US$1.47m||0.018% $400.0k|
|Chief Technology Officer||no data||no data||no data|
|Chief Information Officer||14.5yrs||no data||no data|
|Chief Legal Officer & Corporate Secretary||4.25yrs||US$1.20m||0.00021% $4.7k|
|Vice President of Corporate Communications||no data||no data||no data|
|Vice President of Global Human Resources||13.5yrs||no data||no data|
Experienced Management: MM3's management team is seasoned and experienced (5.8 years average tenure).
|Independent Director||8.67yrs||US$329.90k||0.034% $750.4k|
|Independent Director||0.083yr||no data||no data|
|Independent Director||0.083yr||no data||0.00077% $17.1k|
|Independent Director||5yrs||US$329.90k||0.020% $449.2k|
|Independent Director||3.17yrs||US$329.90k||no data|
|Independent Director||0.083yr||no data||0.00067% $14.8k|
|Independent Director||0.92yr||US$187.15k||no data|
Experienced Board: MM3's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Merit Medical Systems, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Merit Medical Systems, Inc.
- Ticker: MM3
- Exchange: DB
- Founded: 1987
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$2.490b
- Listing Market Cap: US$2.215b
- Shares outstanding: 55.38m
- Website: https://www.merit.com
Number of Employees
- Merit Medical Systems, Inc.
- 1600 West Merit Parkway
- South Jordan
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MMSI||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 1990|
|MM3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1990|
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, interventional fluid management, pressure monitoring, and cardiac rhythm management, as well as thermodilution and pulmonary artery catheters and electrophysiology to treat various heart conditions. It also offers cardiovascular and critical care products to treat patients with life-threatening diseases, and protect healthcare providers from exposure to bloodborne pathogens. In addition, it provides interventional oncology and spine products to treat vertebral compression fractures, metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, it offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; microelectromechanical system sensor components; ConvertX nephroureteral stent system; and Fibrovein, a detergent-based sclerosant. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was founded in 1987 and is headquartered in South Jordan, Utah.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/02 22:16|
|End of Day Share Price||2020/07/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.